Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.

Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA).; ART Cohort Collaboration., Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Miro JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borght S, Schechter M.

Clin Infect Dis. 2007 Dec 1;45(11):1518-21.

2.

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.

Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration.; ART Cohort Collaboration (ART-CC) groups..

Lancet. 2006 Mar 11;367(9513):817-24. Erratum in: Lancet. 2006 Jun 10;367(9526):1902.

PMID:
16530575
3.

Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries.

Lawn SD, Wood R.

Clin Infect Dis. 2005 Dec 15;41(12):1783-6. No abstract available.

PMID:
16288404
4.

Risk of tuberculosis following HIV seroconversion in high-income countries.

Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord..

Thorax. 2013 Mar;68(3):207-13. doi: 10.1136/thoraxjnl-2012-201740.

PMID:
23117980
5.

CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.

Collins SE, Jean Juste MA, Koenig SP, Secours R, Ocheretina O, Bernard D, Riviere C, Calnan M, Dunning A, Hurtado RĂșa SM, Johnson WD Jr, Pape JW, Fitzgerald DW, Severe P.

Int J Tuberc Lung Dis. 2015 Jan;19(1):50-7. doi: 10.5588/ijtld.14.0217.

PMID:
25519790
6.

Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.

Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D, Sprinz E, Dabis F, Harrison LH, Schechter M.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):52-9.

PMID:
17460471
7.

Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR.

J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):305-10. doi: 10.1097/QAI.0b013e3182182e2d.

8.

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, Thawornwan U, Suntisuklappon B, Nilkamhang S, Sungkanuparph S; TIME Study Team..

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):377-83. doi: 10.1097/QAI.0b013e31825b5e06.

PMID:
22592586
9.

Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries.

Achhra AC, Phanuphak P, Amin J.

Curr Opin HIV AIDS. 2011 Jul;6(4):258-65. doi: 10.1097/COH.0b013e3283476c72. Review.

PMID:
21546834
10.

Effect of antiretroviral treatment on the risk of tuberculosis during South Africa's programme expansion.

Bachmann MO, Timmerman V, Fairall LR.

AIDS. 2015 Nov;29(17):2261-8. doi: 10.1097/QAD.0000000000000806.

PMID:
26544699
11.

Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia.

Choun K, Thai S, Pe R, Lorent N, Lynen L, van Griensven J.

Trans R Soc Trop Med Hyg. 2013 Apr;107(4):235-42. doi: 10.1093/trstmh/trt001.

PMID:
23324313
12.

Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection.

Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, Ippolito G; Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA)..

AIDS. 2000 Sep 8;14(13):1985-91.

PMID:
10997404
13.

Tuberculin skin test conversion among HIV patients on antiretroviral therapy in Uganda.

Kirenga BJ, Worodria W, Massinga-Loembe M, Nalwoga T, Manabe YC, Kestens L, Colebunders R, Mayanja-Kizza H.

Int J Tuberc Lung Dis. 2013 Mar;17(3):336-41. doi: 10.5588/ijtld.12.0298.

PMID:
23407223
14.

Effectiveness of antiretroviral treatment in a South African program: a cohort study.

Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD.

Arch Intern Med. 2008 Jan 14;168(1):86-93. doi: 10.1001/archinternmed.2007.10.

PMID:
18195200
15.

Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines.

Nelson LJ, Beusenberg M, Habiyambere V, Shaffer N, Vitoria MA, Montero RG, Easterbrook PJ, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S217-24. doi: 10.1097/QAD.0000000000000239.

PMID:
24849481
16.

Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort.

Tilley DM, Griggs E, Hoy J, Wright ST, Woolley I, Burke M, O'Connor CC; Australian HIV Observational Database (AHOD)..

AIDS Care. 2015;27(11):1410-7. doi: 10.1080/09540121.2015.1113227.

PMID:
26679270
17.

The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy.

Stover J, Gopalappa C, Mahy M, Doherty MC, Easterbrook PJ, Weiler G, Ghys PD.

AIDS. 2014 Mar;28 Suppl 2:S225-30. doi: 10.1097/QAD.0000000000000235.

PMID:
24849482
18.

Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.

Bwire R, Nagelkerke NJ, Borgdorff MW.

Trop Med Int Health. 2006 Oct;11(10):1567-75.

19.

Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.

Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC.

AIDS. 2003 Dec 5;17(18):2615-22.

PMID:
14685055
20.

Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings.

Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, Du Cros P, Casas EC, Da Fonseca MS, O'Brien DP.

PLoS One. 2012;7(12):e52019. doi: 10.1371/journal.pone.0052019.

Supplemental Content

Support Center